Year-end Sale % OFF 
Abstract
The COVID-19 pandemic has been associated with a disruption of care and worsening outcomes of patients with liver disease.1 Fortunately, receipt of 2 doses of mRNA vaccine was associated with a 78.6% reduction in COVID-19 infection in cirrhosis.2 Although mRNA vaccines have been more widely administered in the United States, viral vector vaccines that use replication-deficient viral vectors, such as adenovirus to induce transient expression of the SARS-CoV-2 spike protein, have been the mainstay of COVID-19 vaccination worldwide.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
